National Technical Reports Library

Details

Tier II Mutagenic Screening of 13 NIOSH Priority Compounds, Individual Compound Report, BIS(2-Methoxyethyl) Ether.

PB83138198

Publication Date	1981
Personal Author	McGregor, D. B.
Page Count	196
Abstract	Bis(2-methoxyethyl)-ether (111966) (BME) was subjected to a tier II mutagenic screening program. Screening assays included unscheduled DNA synthesis (UDS) assay in human diploid fibroblasts with exposures of 3 hours duration and concentrations up to 19,000 micrograms per milliliter of culture medium; dominant lethal test in male rats with exposures to atmospheres containing 250 parts per million (ppm) or 1000ppm BME for 7 hours per day for 5 days; sperm abnormality test in male mice using the same exposures conditions; cytogenetic test in male and female rat bone marrow cells using the same exposure conditions or a single exposure of 7 hours duration; sex-linked recessive lethal test in Drosophila-melanogaster with exposure to atmospheres of 250ppm for 2.75 hours. There was no increase in UDS in cells treated with BME; clinical signs of toxicity occurred in animals exposed to 1000ppm BME atmospheres; male rat fertility was drastically reduced following exposure to 1000ppm BME in the dominant lethal test; a significant reduction in total aberrant cell frequency occurred; and abnormal sperm frequency was increased. The author concludes that BME may be a weak mutagen, but the adverse effect upon reproductive capacity is probably the more important aspect of its toxicology.
Keywords	Bioassay Toxicology Humans Exposure Fertility Genetics Rats Laboratory animals Mutagens Oxygen organic compounds Ether/bis(methoxyethyl) Mutagenesis CAS 111-96-6 Medical research Health screening
Source Agency	National Institute for Occupational Safety and Health
NTIS Subject Category	57Y - Toxicology 57E - Clinical Medicine
Corporate Authors	Inveresk Research International Ltd., Musselburgh (Scotland).; National Inst. for Occupational Safety and Health, Cincinnati, OH.
Supplemental Notes	See also PB83-113407.
Document Type	Technical Report
NTIS Issue Number	198305
Contract Number	PHS-NIOSH-210-78-0026

Tier II Mutagenic Screening of 13 NIOSH Priority Compounds, Individual Compound Report, BIS(2-Methoxyethyl) Ether.

Tier II Mutagenic Screening of 13 NIOSH Priority Compounds, Individual Compound Report, BIS(2-Methoxyethyl) Ether.
PB83138198

Publication Date	1981
Personal Author	McGregor, D. B.
Page Count	196
Abstract	Bis(2-methoxyethyl)-ether (111966) (BME) was subjected to a tier II mutagenic screening program. Screening assays included unscheduled DNA synthesis (UDS) assay in human diploid fibroblasts with exposures of 3 hours duration and concentrations up to 19,000 micrograms per milliliter of culture medium; dominant lethal test in male rats with exposures to atmospheres containing 250 parts per million (ppm) or 1000ppm BME for 7 hours per day for 5 days; sperm abnormality test in male mice using the same exposures conditions; cytogenetic test in male and female rat bone marrow cells using the same exposure conditions or a single exposure of 7 hours duration; sex-linked recessive lethal test in Drosophila-melanogaster with exposure to atmospheres of 250ppm for 2.75 hours. There was no increase in UDS in cells treated with BME; clinical signs of toxicity occurred in animals exposed to 1000ppm BME atmospheres; male rat fertility was drastically reduced following exposure to 1000ppm BME in the dominant lethal test; a significant reduction in total aberrant cell frequency occurred; and abnormal sperm frequency was increased. The author concludes that BME may be a weak mutagen, but the adverse effect upon reproductive capacity is probably the more important aspect of its toxicology.
Keywords	Bioassay Toxicology Humans Exposure Fertility Genetics Rats Laboratory animals Mutagens Oxygen organic compounds Ether/bis(methoxyethyl) Mutagenesis CAS 111-96-6 Medical research Health screening
Source Agency	National Institute for Occupational Safety and Health
NTIS Subject Category	57Y - Toxicology 57E - Clinical Medicine
Corporate Authors	Inveresk Research International Ltd., Musselburgh (Scotland).; National Inst. for Occupational Safety and Health, Cincinnati, OH.
Supplemental Notes	See also PB83-113407.
Document Type	Technical Report
NTIS Issue Number	198305
Contract Number	PHS-NIOSH-210-78-0026